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try, respectively and to a lesser extent in non-AMI TO pts from 63% in the 1985-86 Regis-
try to 81%, 77%, and 78% in Waves 1-3 of the Dynamic Registry, respectively ( both
P<0.0001). Inability to cross the lesion was the most common reason for failure in both pt
groups. In multivariable analysis, the most consistent predictor of unsuccessful dilation of
TO lesions was location in a bypass graft for both acute MI (OR 6.06, CI 2.67 – 13.77)
and non-AMI pts (OR 4.08, CI 1.61 – 10.3). For non-AMI TO lesions, the presence of
thrombus was associated with success (OR 0.33, CI 0.17-0.63) while being supplied by
collaterals was not (OR 2.10, CI 1.20-3.68). Pt age, gender, smoking status did not pre-
dict failure.
Conclusions: In this investigation, TO lesions were attempted less frequently over time.
Success rates for non-AMI pts were lower than AMI pts, were higher than in the prior
decade but failed to increase above 80%. Increase in success rates could be related to
more restricted patient selection. Factors related to lesion chronicity were associated
with failure to dilate TO lesions in non-AMI pts.
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Background: Intracoronary brachytherapy (ICBT) has previously been shown to be effec-
tive for instent restenosis. Causes of failure have not been widely studied since the tech-
nique gained approval.
Methods: All patients treated with ICBT for instent restenosis in native coronary arteries
at our institution between March 2001 and March 2002 were followed for one year. ICBT
was performed using the Novoste Beta-Cath System (Novoste Corporation) in 248
lesions and the Galileo System (Guidant Corporation) in 7 lesions. The procedures were
performed by 29 cardiologists and 6 radiation oncologists in a busy tertiary care setting
during the first year of approval. Patients with recurrent symptoms or abnormal stress
tests underwent repeat angiography. A panel of two cardiologists and a radiation oncolo-
gist reviewed all angiograms obtained during follow-up and the corresponding baseline
studies. The initial ICBT angiogram was assessed for adequacy of radiation margins with
respect to the injured segment. The follow-up angiograms were assessed for presence of
restenosis in the ICBT segment (TLRS).
Results: A total of 255 lesions were treated in 224 patients during the study period. There
were 139 males (62%). Age of the patients was 66 ± 12 years. Reference vessel diame-
ter, as assessed by the initial operator, was between 3 and 4 mm in 237 lesions (93%)
and less than 3 mm in 18 lesions (7%). Follow-up angiography was performed in 127 of
the treated lesions (50%). The mean duration between ICBT and follow-up angiography
was 200 ± 84 days. TLRS was identified in 20 (7.8%) of the treated lesions. Nine of the
20 patients (45%) were found to have inadequate margins at the time of the initial ICBT
procedure. The remaining 11 patients had documented radiation failure (4.3% of total
treated patients).
Conclusion: Despite a large number of operators, with limited experience using a new
device, failure of ICBT in adequately treated patients was uncommon. The major source
of failure in our series was inadequate margins in the treated segment. Use of longer
radiation sources and diligence in maintaining adequate margins should improve out-
comes.
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Background: Intracoronary radiation therapy (IRT) is established as an effective treat-
ment for in-stent restenosis (ISR). We aimed to determine whether the 6-month clinical
outcomes of patients (pts) treated with market released, post approval radiation are
equivalent to those enrolled in the Washington Radiation for In-Stent restenosis Trials
(WRIST).
Methods: The clinical outcomes of 110 pts with 128 lesions receiving commercially avail-
able IRT (beta 18.4 - 45.7 Gy or gamma 18 Gy) was compared with 117 pts with 117
lesions who received investigational IRT either with gamma (n=65, 192 Ir, 15Gy WRIST)
or beta (n=52, 90Y, 20.6 Gy Beta WRIST). The Investigational Radiation group (IR)
received antiplatelet therapy for 1 mo and the Commercial Radiation group (CR) for 6 mo.
Results: The baseline characteristics were similar. Diabetes 41.7% in CR and 34.2% in
IR. Pts in the CR were treated with wider radiation margins. Use of additional stents was
similar (33.2% in CR vs 38.5% in IR, P=0.34) but atheroablation devices used in CR were
lower than in IR (15.0% vs 72.6%, P<0.001). Major cardiac clinical events; Any MI, TLR,
and TVR were significantly lower in the CR.
Conclusions: The “real world” clinical practice of IRT demonstrates lower events and
better clinical outcomes when compared with patients treated during the investigational
IRT trials. This is most likely a result of implementation of the lessons learned from the
clinical trials primarily using higher doses, wider margins and prolonged antiplatelet ther-
apy.
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Background: Treatment of in-stent restenosis (ISR) with intracoronary radiation therapy
(IRT) has become the mainstay of revascularization therapy. However, radiation failure,
which presents as either occlusion or restenosis, occurs in up to 25% of patients. Late
thrombotic occlusion (LTO) is the major cause for radiation related morbidity. This study
aimed to compare the outcomes of patients with LTO versus patients with renarrowing
without LTO after intracoronary radiation.
Methods: Five hundred thirty-three patients who failed previous gamma or beta radiation
presented with angiographic evidence of LTO (n=283) or renarrowing (n=248). Patients
were followed for a mean of 423.8 ± 408.8 days after the date of failure and the clinical
outcome was compared.
Results: Prevalence of prior MI and CABG was higher in patients with LTO (P=0.02,
P=0.009; respectively). Other angiographical and clinical baseline characteristics were
comparable between the two groups. Six- and 12-month clinical outcomes are displayed
in the table. TVR-MACE rates after 6 and 12 months was higher in patients presenting
with LTO versus patients without LTO (P=0.001, respectively); whereas death and Q-
wave MI rates were similar in both groups.
Conclusions: Patients with LTO after intracoronary radiation therapy for ISR are at an
increased risk for major cardiac events at 6 and 12 months. Prolonged antiplatelet ther-
apy is mandatory to prevent LTO. These patients may require special care once pre-
sented with LTO.
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Background: It has been shown that survival improves following successful percutane-
ous coronary intervention (PCI) of chronic total occlusions (CTO). This study describes
the clinical and demographic factors associated with decreased long-term survival in a
large cohort of patients undergoing PCI of a CTO.
Methods: The Mid-America Heart Institute has maintained a registry of all coronary
interventions. 2,687 PCIs for CTO were performed between June 1980 and May 2003.
Clinical predictors of 5-year survival were examined to identify those variables that may
assist the physician in weighing the risk:benefit ratio of revascularization. Univariate pre-
dictors of mortality were entered into a multivariable logistic regression analysis and are
presented here.
Results: The highest odds ratio for death after PCI to a CTO was found in those with
poor left ventricular systolic function (ejection fraction <40%). History of heart failure and
chronic renal insufficiency were associated with greater than doubling of the mortality
rate.
Conclusions: These data highlight the adverse effect of these demographic and clinical
variables on outcomes after PCI upon CTO. This should not discourage the use of PCI,
as it does relieve angina, and may improve long-term survival if successful. Rather, it
Table. Clinical Events at 6 Months
Commercial IRT n (%) Investigational IRT n (%) P
Death 6/110 (5.5) 5/117 (4.3) 0.68
Any MI 3/110 (2.7) 16/117 (13.7) 0.003
Any Revascularization 20/124 (16.1) 40/117 (34.2) 0.001
TLR 11/128 (8.6) 27/117 (23.1) 0.002
TVR 15/128 (11.7) 35/117 (29.9) <0.001
All MACE 15/110 (13.6) 36/117 (30.8) 0.002
Table. Six and 12-month clinical outcomes of LTO vs no-LTO
Restenosis without LTO 
(n=283)
Restenosis with LTO 
(n=248)
P 
Value
Clinical outcome at 6 
months
TVR MACE, n (%) 58 (26.0) 80 (41.0) 0.001
TLR, n (%) 45 (20.2) 63 (32.6) 0.004
Clinical outcome at 12 
months
TVR MACE, n (%) 67 (36.4) 86 (54.1) 0.001
TLR, n (%) 51 (27.7) 66 (41.5) 0.008
